These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33459070)

  • 1. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature.
    Skulimowski A; Durczyński A; Strzelczyk J; Hogendorf P
    Biomarkers; 2021 Jun; 26(4):287-295. PubMed ID: 33459070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
    Luo G; Xiao Z; Long J; Liu Z; Liu L; Liu C; Xu J; Ni Q; Yu X
    J Gastrointest Surg; 2013 Dec; 17(12):2092-8. PubMed ID: 24146342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
    Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
    Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
    O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
    Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
    He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
    BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
    Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
    Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
    Bian J; Sun X; Li B; Ming L
    Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
    Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
    Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
    Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
    BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
    Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
    Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
    Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
    Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
    Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
    Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
    Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
    Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
    Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
    Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.